Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Five-year follow up of the UK CLL Forum ibrutinib data

George Follows • 20 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Ibrutinib

George Follows, BCh, PhD, FRCP, FRCPath, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, updates us on the UK CLL Forum 5-year follow up data for ibrutinib in R/R chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from George Follows

Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse 1:21
Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
George Follows • 2 May 2018
PEP-C for treatment of relapsed/refractory lymphoma 1:11
PEP-C for treatment of relapsed/refractory lymphoma
George Follows • 2 May 2018
MURANO study: exciting times in CLL 2:06
MURANO study: exciting times in CLL
George Follows • 9 Dec 2017
Copanlisib for relapsed/refractory NHL: results of the CHRONOS-1 study 1:22
Copanlisib for relapsed/refractory NHL: results of the CHRONOS-1 study
George Follows • 9 Dec 2017

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals